Olverembatinib is a targeted therapy medication known as a tyrosine kinase inhibitor (TKI). It works by blocking specific proteins that contribute to cancer cell growth in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. This medication is given in combination with chemotherapy drugs to treat newly diagnosed patients.

Tyrosine Kinase Inhibitors (TKIs) are a class of medications that work by blocking specific proteins involved in cancer cell growth. In this trial, various TKIs are used as comparison treatments, combined with chemotherapy, according to the investigator’s choice.

Chemotherapy refers to traditional cancer-fighting medications that work by killing rapidly dividing cells in the body. These medications are used in combination with either olverembatinib or other TKIs to treat leukemia.

Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) – A type of blood and bone marrow cancer where the body produces abnormal white blood cells containing a specific genetic mutation called the Philadelphia chromosome. The disease develops rapidly, with abnormal lymphoid cells (lymphoblasts) multiplying quickly and replacing normal blood cells in the bone marrow. These malignant cells eventually spread into the bloodstream and can infiltrate other organs. The condition affects the body’s ability to produce normal blood cells, leading to decreased production of red blood cells, platelets, and healthy white blood cells. The presence of the Philadelphia chromosome makes this form of leukemia distinct from other types of acute lymphoblastic leukemia.